6-氟-2-(三丁基锡)吡啶 | 1025744-38-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氟-2-(三丁基锡)吡啶
• 中文别名: 2-氟-6-(三丁基锡)吡啶
• 英文名称: 2-fluoro-6-(tributylstannyl)pyridine
• 英文别名: tributyl(6-fluoro-2-pyridyl)stannane；tributyl-(6-fluoropyridin-2-yl)stannane
• CAS: 1025744-38-0
• 化学式: C₁₇H₃₀FNSn
• 分子量: 386.14
• InChiKey: REDITYHAUYWHPX-UHFFFAOYSA-N

物化性质

• 沸点：
  385.8±52.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.28
• 重原子数：
  20
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  6-氟-2-(三丁基锡)吡啶 在 N-甲基吗啉 、 盐酸 、 四(三苯基膦)钯 、 copper(l) chloride 、 lithium chloride 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 、 二甲基亚砜 为溶剂， 反应 37.0h， 生成 3-(6-(1,4-diazepan-1-yl)pyridin-2-yl)-5-(6-methylpyrazin-2-yl)isothiazolo[5,4-c]pyridine
  参考文献：
  名称：

  Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability

  摘要：

  Pim kinases have been identified as promising therapeutic targets for hematologic-oncology indications, including multiple myeloma and certain leukemia. Here, we describe our continued efforts in optimizing a lead series by improving bioavailability while maintaining high inhibitory potency against all three Pim kinase isoforms. The discovery of extensive intestinal metabolism and major metabolites helped refine our design strategy, and we observed that optimizing the pharmacokinetic properties first and potency second was a more successful approach than the reverse. In the resulting work, novel analogs such as 20 (GNE-955) were discovered bearing 5-azaindazole core with noncanonical hydrogen bonding to the hinge.

  DOI：

  10.1021/acs.jmedchem.7b00418

文献信息

• [EN] TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE DÉGRADATION DE RÉCEPTEURS À ACTIVITÉ KINASE LIÉS À LA TROPOMYOSINE (TRK) ET MÉTHODES D'UTILISATION
  申请人：CULLGEN SHANGHAI INC

  公开号：WO2021170109A1

  公开（公告）日：2021-09-02

  This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

  这份披露涉及双价化合物（例如，双功能小分子化合物），包含一种或多种双价化合物的组合物，以及利用这些双价化合物治疗患有特定疾病的受试者的方法。该披露还涉及识别此类双价化合物的方法。
• [EN] MODIFIED PROTEINS AND PROTEIN DEGRADERS<br/>[FR] PROTÉINES MODIFIÉES ET AGENTS DE DÉGRADATION DE PROTÉINES
  申请人：CULLGEN SHANGHAI INC

  公开号：WO2021239117A1

  公开（公告）日：2021-12-02

  Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

  本文提供了结合或降解靶蛋白的化合物、药物组合物和方法。本文还提供了具有DNA损伤结合蛋白1（DDB1）结合基团的化合物。其中一些实施例包括连接物。其中一些实施例包括靶蛋白结合基团。本文还提供了配体-DDB1复合物。本文还提供了体内修饰的DDB1蛋白。
• 8-Substituted isoquinoline derivative and the use thereof
  申请人：Kaneko Shunsuke

  公开号：US20100261701A1

  公开（公告）日：2010-10-14

  The present invention relates to a compound represented by the following formula (1): wherein D 1 , A 1 , D 2 , R 1 , D 3 , and R 2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.

  本发明涉及一种由以下式（1）表示的化合物： 其中D1，A1，D2，R1，D3和R2分别具有与本说明书中定义的相同含义或其盐。由式（1）表示的化合物或其盐具有IKKβ抑制活性等，对于预防和/或治疗IKKβ相关疾病或症状等方面是有用的。
• [EN] RING-ANNULATED DIHYDROPYRROLO[2,L-A]ISOQUINOLINES<br/>[FR] DIHYDROPYRROLO[2,1-A]ISOQUINOLÉINES CONDENSÉES À UN NOYAU
  申请人：ORGANON NV

  公开号：WO2011012600A1

  公开（公告）日：2011-02-03

  The invention relates to ring-annulated dihydropyrrolo[2,1-a]isoquinoline compounds according to general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.

  该发明涉及按照通用式(I)或其药学上可接受的盐制备的环融合二氢吡咯并[2,1-a]异喹啉化合物。这些化合物可用于治疗不孕症。
• Ring-annulated dihydropyrrolo[2,1-alpha]isoquinolines
  申请人：Timmers Cornelis Marius

  公开号：US20110028450A1

  公开（公告）日：2011-02-03

  The invention relates to ring-annulated dihydropyrrolo[2,1-a]isoquinoline compounds according to general Formula I or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.

  这项发明涉及符合通用式I的环融合二氢吡咯并[2,1-a]异喹啉化合物或其药用可接受的盐。这些化合物可用于治疗不孕症。